Lexington, MA – According to filings with the U.S. Securities and Exchange Commission, Cyteir Therapeutics is raising $79,999,980.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Markus Renschler played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cyteir Therapeutics

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer. Through a unique cancer treatment approach, Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

To learn more about Cyteir Therapeutics, visit http://cyteir.com/

Contact:
Markus Renschler, President and Chief Executive Officer
857-285-4140
markus.renschler@cyteir.com
https://www.linkedin.com/in/markus-renschler-md-1b103072/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved